Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abandonment, absolute, albeit, ASC, Austria, authoritative, blended, Branford, byASC, CareFusion, carryforward, Codification, Codificationtm, CODM, collusion, Combinationswhen, commingled, Compensationand, Compensationin, Compensationthe, core, curve, Danaher, DisclosuresandASC, divisional, earliest, Equipmentof, era, ERISA, error, fact, faulty, fit, fourteen, Graduate, GS, hereunder, inASC, inception, inseparable, insignificant, issuedThe, Keck, length, literature, maker, MBS, medial, mistake, modification, nonauthoritative, nongovernmental, nongrandfathered, nonperformance, ObligationsandEmerging, ofASC, onASC, OptionsandASC, Optionswith, orderly, override, package, passed, pre, prep, prescribed, profile, profiling, progressing, proportionally, publicly, qualification, ratified, reader, recurring, redefined, relationship, release, Reportingto, retention, seventy, shape, Sharerequired, simple, solvency, Southern, stake, straight, succeed, superseded, surrender, Taxesreflected, technique, Thailand, toASC, topic, transparency, underasc, underEITF, underThe, underway, underwriting, unearned, Unvested, updatingASC, VSOE, withASC, withThe
Removed:
accretion, actuarially, advertise, amplification, APB, appointed, automation, awarded, bio, biomolecular, Burnham, Caltag, capturing, career, cascade, categorized, choose, Christchurch, collectible, contingently, creation, cultured, customary, disrupt, Electric, emphasize, experimentation, expired, FBS, FIN, GIBCO, Glasgow, guideline, harming, improvement, initiative, intersegment, investigative, involuntarily, irrevocable, kit, lender, live, logical, manipulation, matched, month, naturally, NIBOR, Nominating, Norwegian, oligonucleotide, ORF, output, permanent, productivity, proforma, proposed, purity, reimbursable, relevance, reportable, resale, segregate, segregation, Sentigen, shared, shortly, simulate, sourced, stable, step, subgrouping, submitted, syndicated, unallocated, unbilled, Uncertainty, validated, viable, violate, vote, worth, Xcyte, Zymed
Filing tables
Filing exhibits
Related press release
aTyr Pharma similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Form S-3 Nos. 333-164880, 333-164823, 333-128387, 333-115611, 333-84134, 333-37964, 333-52896 and 333-110060; Form S-4 Nos. 333-43674, 333-82593, 333-120330, and 333-152741; and Form S-8 Nos. 333-46146, 333-36606, 333-86531, 333-74061, 333-105730, 333-108291, 333-108442, 333-115447, 333-155809, 333-158953, 333-158954 and 333-159105) of Life Technologies Corporation and in the related Prospectuses of our reports dated February 26, 2010, with respect to the consolidated financial statements and schedule of Life Technologies Corporation and the effectiveness of internal control over financial reporting of Life Technologies Corporation, included in this Annual Report (Form 10-K) for the year ended December 31, 2009.
/s/ Ernst & Young LLP |
San Diego, California
February 26, 2010
February 26, 2010